🇺🇸 FDA
Patent

US 12371747

Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy

granted A61KA61K2039/6031A61K2039/6056

Quick answer

US patent 12371747 (Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy) held by BIOVERATIV THERAPEUTICS INC. expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BIOVERATIV THERAPEUTICS INC.
Grant date
Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K2039/6031, A61K2039/6056, A61K38/21, A61K38/37